Monika Chaszczewska-Markowska

Monika Chaszczewska-Markowska

Auto-generated profile, based on publicly available information

Monika Chaszczewska-Markowska

Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2016 in Postępy Higieny I Medycyny Doświadczalnej
Verified
Journal Article
Open access
MCMonika Chaszczewska-Markowska
Monika Chaszczewska-Markowska
MSMaria Sagan
Maria Sagan
KBKatarzyna Bogunia-Kubik
Katarzyna Bogunia-Kubik
Secretion of renin juxtaglomerular cells into bloodstream initiates activation of an enzymatic-hormonal cascade known as the RAAS (renin - angiotensin - aldosterone system). As a result, blood pressure is increased by the means several interrelated mechanisms. Mechanism of Zjednoczoaction of this system has been known for decades, but a few previously unknown components were recently added, such as ACE-2 and Ang(1-7), and their role often seems to be opposite to that of the conventional components. Local tissue systems also have important biological functions. They operate largely independently of the systemic activity, and their activity is observed primarily in the kidney, heart, in blood vessels, adrenal gland and nervous system. Angiotensin-2 (Ang-2), the main RAAS effector, has a wide scope of action, and thus abnormalities in its functioning have many consequences. Excessive activation is accompanied by chronic inflammation, as Ang-2 stimulates inflammatory mediators. As a result, degenerative processes and atherosclerosis are initiated. RAAS imbalance is associated with the most common diseases of civilization, such as cardio-vascular diseases, diabetes, kidney diseases, preeclampsia, osteoporosis and even neurodegenerative diseases. Many of these pathological processes are attributed to the excessive activation of tissue RA system. Therapeutic strategies based on inhibition of the RAAS are commonly used mainly in the treatment of hypertension and other cardiovascular disorders. The benefits of this class of drugs is primarily a decrease in blood pressure, but also the suppression of inflammatory processes and other pathological phenomena resulting from excessive activation of the RAAS. For that reason, some consider to use RAAS inhibitors in other diseases, e.g. Parkinson's disease. Further studies give hope for the improvement of RAAS inhibitor therapy and the development of new therapeutic strategies.

1 April 2008 in Cancer Letters
Verified
Journal Article
Closed access
MCMonika Chaszczewska-Markowska
Monika Chaszczewska-Markowska
KSKatarzyna Stebelska
Katarzyna Stebelska
ASAleksander F. Sikorski
Aleksander F. Sikorski
JMJanusz Madej
Janusz Madej
AOAdam Opolski
Adam Opolski
MUMaciej Ugorski
Maciej Ugorski

1 January 2021 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
JWJoanna Wielińska
Joanna Wielińska
JŚJerzy Świerkot
Jerzy Świerkot
KKKatarzyna Kolossa
Katarzyna Kolossa
BBBartosz Bugaj
Bartosz Bugaj
MCMonika Chaszczewska-Markowska
Monika Chaszczewska-Markowska
KBKatarzyna Bogunia-Kubik
Katarzyna Bogunia-Kubik
IL‐17A and IL‐17F together with their coreceptor (IL‐17RA/RC) were reported to play a significant role in the pathogenesis of spondyloarthritis. The group of axial spondyloarthritis comprises ankylosing spondylitis (AS), a rheumatic disease characterized by chronic inflammation of the joints in the spine. This study is aimed at investigating IL-17A, IL-17F, IL-17RA, and IL-17RC polymorphisms as potential biomarkers of disease susceptibility, clinical parameters, and anti‐TNF treatment outcome in a cohort of Polish ankylosing spondylitis patients. In total, 328 subjects, including 138 AS patients and 190 healthy volunteers, participated in the study. Genotyping of IL-17A rs2275913 (G/A), IL-17F rs763780 (A/G), IL-17RA rs4819554 (A/G), and IL-17RC rs708567 (G/A) was performed on real‐time PCR instrument using LightSNiP assays. No significant differences were revealed in genotype and allele distribution between patients and controls despite the association of the IL-17RC rs708567 AA homozygosity with the earlier onset of the disease. Moreover, some relationships between IL-17F rs763780 and IL-17RA rs4819554 polymorphisms with clinical parameters related to the disease activity and anti‐TNF treatment outcome were observed. IL-17F rs763780 G allele was found to be associated with high disease activity and BASDAI after 6 months and poor response to the treatment while higher VAS values were more common among IL-17RA rs4819554 G variant carriers. In conclusion, the IL-17F rs763780 polymorphism should be considered as a promising biomarker of disease activity and anti‐TNF treatment outcome. The IL-17RA rs48419554 G allele may serve as a potential marker of disease severity in Polish AS patients.

1 December 2016 in Archivum Immunologiae et Therapiae Experimentalis
Verified
Journal Article
Open access
PDF file
ABAleksandra Butrym
Aleksandra Butrym
PŁPiotr Łacina
Piotr Łacina
JRJustyna Rybka
Justyna Rybka
MCMonika Chaszczewska-Markowska
Monika Chaszczewska-Markowska
GMGrzegorz Mazur
Grzegorz Mazur
KBKatarzyna Bogunia-Kubik
Katarzyna Bogunia-Kubik
Multiple myeloma (MM) is a plasma-cell malignancy derived from an early precursor of the B-cell lineage characterised by bone-marrow infiltration, lytic bone lesions, and the presence of a monoclonal protein in serum and/or urine. Interferon regulatory factor 4 (IRF4) is a critical transcriptional regulator in B-cell development and function that is required during immune response for lymphocyte activation and the generation of immunoglobulin-secreting plasma cells. Immunomodulatory drugs, derivatives of thalidomide, are commonly used in therapy against MM. They are known to target a protein called cereblon (CRBN); however, the exact mechanism remains unknown. The present study aimed to assess the association of two (rs12203592 and rs872071) polymorphisms within the IRF4 gene and two (rs711613 and rs1045433) in the CRBN gene with MM susceptibility, progression, and response to treatment. For this purpose, 144 MM patients and 126 healthy individuals were genotyped for the IRF4 and CRBN alleles. The presence of the IRF4 (rs872071) G allele was more frequently detected in patients than healthy individuals (OR 1.78; P = 0.034), and this relationship was especially pronounced in women (OR 2.83; P = 0.012). The CRBN (rs711613) A allele-carriers were better responders to the treatment (P = 0.012), in particular to thalidomide including therapy (P = 0.023). These results underline the prognostic significance of the IRF4 and CRBN polymorphisms in patients with MM.

1 April 2019 in Cytokine
Verified
Journal Article
Closed access
KGKatarzyna Gębura
Katarzyna Gębura
ABAleksandra Butrym
Aleksandra Butrym
MCMonika Chaszczewska-Markowska
Monika Chaszczewska-Markowska
TWTomasz Wróbel
Tomasz Wróbel
KKKazimierz Kuliczkowski
Kazimierz Kuliczkowski
KBKatarzyna Bogunia-Kubik
Katarzyna Bogunia-Kubik

1 August 2018 in Respiratory Physiology & Neurobiology
Verified
Journal Article
Closed access
PJPrzemysław Jaźwiec
Przemysław Jaźwiec
Paweł GaćPaweł Gać
Paweł Gać
MCMonika Chaszczewska-Markowska
Monika Chaszczewska-Markowska
KBKatarzyna Bogunia-Kubik
Katarzyna Bogunia-Kubik
GMGrzegorz Mazur
Grzegorz Mazur
RPRafał Poręba
Rafał Poręba